Home         Forums  

Go Back   Marrowforums > Treatments > Clinical Trials
Register FAQ Search Today's Posts Mark Forums Read

Clinical Trials Considering or participating in research studies

Reply
 
Thread Tools Search this Thread
  #1  
Old Fri Feb 1, 2013, 07:04 AM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
New drug for anemia in the pipeline

Hi All,
A new drug for anemia is now tested in a Phase II trial:
http://www.checkorphan.org/grid/news...stic-syndromes
Kind regards
Birgitta-A
Reply With Quote
  #2  
Old Fri Feb 1, 2013, 11:49 AM
Neil Cuadra Neil Cuadra is offline
Owner
 
Join Date: Jul 2006
Location: Los Angeles, California
Posts: 2,553
The Acceleron press release has these quotes from the investigators:
The anemia experienced by patients with MDS is clinically challenging because it is often unresponsive to administration of erythropoietin and many patients ultimately require red blood cell transfusions.

ACE-536 has the potential to make a significant impact on the treatment of anemia in MDS. Unlike erythropoietin, ACE-536 may target the specific defect in the erythropoietic maturation process in MDS patients and we are optimistic that it could become an important new therapeutic option for this underserved patient population.
An additional bit of information from the Acceleron product page:
In preclinical studies, ACE-536 promoted RBC formation in the absence of erythropoietin (EPO) signaling, had distinct effects from EPO on RBC differentiation, and acted on a different population of progenitor blood cells than EPO during RBC development.
Reply With Quote
  #3  
Old Fri Feb 1, 2013, 02:46 PM
riccd2001 riccd2001 is offline
Member
 
Join Date: Aug 2010
Location: Burlington,Ontario,Canada
Posts: 186
Thanks Birgitta and Neil for the links. There's still more to do but these are very encouraging words in the PR...

"In a phase 1 clinical study of healthy volunteers, ACE-536 produced a dose-dependent increase in red blood cells and hemoglobin levels. "
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
Reply With Quote
  #4  
Old Wed Apr 17, 2013, 06:46 PM
riccd2001 riccd2001 is offline
Member
 
Join Date: Aug 2010
Location: Burlington,Ontario,Canada
Posts: 186
Progress takes time... latest press release

Very good to see progress with FDA classification for ACE-536 !!

http://www.acceleronpharma.com/2013/...s-for-ace-536/
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
AMY-101 for PNH Gains Orphan Drug Status Marrowforums PNH 0 Wed Nov 26, 2014 01:01 AM
Magic drug causes remission, what next? rar MDS 12 Mon May 26, 2014 02:58 PM
What is the case FOR drug therapy?? GaryV Drugs and Drug Treatments 11 Thu Nov 4, 2010 08:37 PM


All times are GMT -4. The time now is 11:03 AM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org